Citations as recorded by:

1. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

Journal of Market Access & Health Policy, 2017, 5(1) p. 1345580

DOI: 10.1080/20016689.2017.1345580

Citations as recorded by: Cross Ref PMC Google

2. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab

Rheumatol Int, 2017, 37(6) p. 1007

DOI: 10.1007/s00296-017-3663-z

Citations as recorded by: Cross Ref Google

3. Defining and Measuring the Affordability of New Medicines: A Systematic Review

PharmacoEconomics, 2017, 35(8) p. 777

DOI: 10.1007/s40273-017-0514-4

Citations as recorded by: Cross Ref Google

4. Access to biologicals in Crohn’s disease in ten European countries

WJG, 2017, 23(34) p. 6294

DOI: 10.3748/wjg.v23.i34.6294

Citations as recorded by: Cross Ref PMC

5. Rheumatoid arthritis is associated with rs17337023 polymorphism and increased serum level of the EGFR protein

PLoS ONE, 2017, 12(7) p. e0180604

DOI: 10.1371/journal.pone.0180604

Citations as recorded by: Cross Ref PMC Google

6. Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe

Journal of Dermatological Treatment,

DOI: 10.1080/09546634.2017.1329509

Citations as recorded by: Cross Ref Google

7. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database

Seminars in Arthritis and Rheumatism,

DOI: 10.1016/j.semarthrit.2017.08.007

Citations as recorded by: Cross Ref

8. Persistence of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis: An analysis of the South Korean National Health Insurance …

Year: 2017

Citations as recorded by: Google

9. Economic aspects of biosimilar competition in Hungary—The treatment of rheumatic disorders

Year: 2017

Citations as recorded by: Google

10. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD

Rheumatology, 2016, 55(7) p. 1217

DOI: 10.1093/rheumatology/kew048

Citations as recorded by: Cross Ref

11. Access to care for multiple sclerosis in times of economic crisis in Greece–the HOPE II study

Year: 2016

Citations as recorded by: Google

12. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian …

Year: 2016

Citations as recorded by: Google

13. Frequency of the use of biological treatment of patients with rheumatoid arthritis and ankylosing spondylitis in Lower Silesia

Year: 2016

Citations as recorded by: Google

14. EFFECT OF THERAPY WITH ANTI-TNF α DRUGS AND DMARD ON DISEASE ACTIVITY AND HEALTH RELATED QUALITY OF LIFE AMONG WOMEN WITH …

Year: 2016

Citations as recorded by: Google

15. CONCOMITANT FIBROMYALGIA IN RHEUMATOID ARTHRITIS: CHALLENGES IN DIAGNOSIS AND DISEASE ASSESSMENT.

Year: 2016

Citations as recorded by: Google

16. Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D

Arthritis & Rheumatology, 2015, 67(6) p. 1474

DOI: 10.1002/art.39079

Citations as recorded by: Cross Ref PMC

17. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

67 p. 1

DOI: 1

Citations as recorded by: Google

18. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers

Rheumatology, 2015, 54(6) p. 1074

DOI: 10.1093/rheumatology/keu446

Citations as recorded by: Cross Ref

19. Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study

Int J Health Policy Manag, 2015, 5(2) p. 83

DOI: 10.15171/ijhpm.2015.173

Citations as recorded by: Cross Ref PMC

20. Biosimilars for the management of rheumatoid arthritis: economic considerations

Expert Review of Clinical Immunology, 2015, 11 p. 43

DOI: 10.1586/1744666X.2015.1090313

Citations as recorded by: Cross Ref Google

21. The role of ultrasonography in assessing disease activity in patients with rheumatoid arthritis and associated fibromyalgia

Year: 2015

Citations as recorded by: Google

22. Inequities in access to biologic and synthetic DMARDs across 46 European countries

Ann Rheum Dis, 2014, 73(1) p. 198

DOI: 10.1136/annrheumdis-2012-202603

Citations as recorded by: Cross Ref Google

23. High Disease Activity May Not Be Sufficient to Escalate Care

Arthritis Care & Research, 2014, 66(2) p. 197

DOI: 10.1002/acr.22098

Citations as recorded by: Cross Ref PMC Google

24. Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews

18(66) p. 1

DOI: 10.3310/hta18660

Citations as recorded by: Cross Ref

25. Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.

Value Health, 2014, 17 p. 8

DOI: 10.1016/j.jval.2014.08.2668

Citations as recorded by: Google

26. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

Eur J Health Econ, 2014, 15 p. 35

DOI: 10.1007/s10198-014-0592-6

Citations as recorded by: Cross Ref Google

27. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic …

Year: 2014

Citations as recorded by: Google

28. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti- …

Year: 2014

Citations as recorded by: Google

29. Biologic therapy in rheumatoid arthritis: results from the Romanian registry of rheumatic diseases one year after initiation

Year: 2014

Citations as recorded by: Google

30. Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation

Rheumatol Int, 2013, 33(6) p. 1379

DOI: 10.1007/s00296-012-2629-4

Citations as recorded by: Cross Ref Google

31. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database

Rheumatol Int, 2013, 33(12) p. 2985

DOI: 10.1007/s00296-013-2833-x

Citations as recorded by: Cross Ref Google

32. Induction of response with etanercept–methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study

Clin Rheumatol, 2013, 32(9) p. 1275

DOI: 10.1007/s10067-013-2240-4

Citations as recorded by: Cross Ref

33. Test–retest reliability of the Disease Activity Score 28 CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints

Clin Rheumatol, 2013, 32(10) p. 1493

DOI: 10.1007/s10067-013-2300-9

Citations as recorded by: Cross Ref

34. Use of Data from Multiple Registries in Studying Biologic Discontinuation: Challenges and Opportunities

Clin Exp Rheumatol, 2013, 31 p. S28

Citations as recorded by: PMC Google

35. Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

Eur J Health Econ, 2013, 14(6) p. 875

DOI: 10.1007/s10198-012-0432-5

Citations as recorded by: Cross Ref

36. Induction of response with etanercept–methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE …

Year: 2013

Citations as recorded by: Google

37. Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

Year: 2013

Citations as recorded by: Google

38. Test–retest reliability of the Disease Activity Score 28 CRP (DAS28-CRP), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) in …

Year: 2013

Citations as recorded by: Google

39. Investigating the value of abatacept in the treatment of rheumatoid arthritis: a systematic review of cost-effectiveness studies

Year: 2013

Citations as recorded by: Google

40. Ассоциативная взаимосвязь генетических маркеров с эффективностью лечения ревматоидного артрита тоцилизумабом

Year: 2013

Citations as recorded by: Google

41. PATIENTS AS A SOURCE FOR COSTS DATA FOR RHEUMATOID ARTHRITIS THERAPY–PILOT STUDY

Year: 2013

Citations as recorded by: Google

42. PA Laires, F. Exposto, R. Mesquita, AP Martins, L. Cunha-Miranda &

Year: 2013

Citations as recorded by: Google

43. Availability and quality of data on drug policy and management of access to reimbursed medicinal products in the United Kingdom, Denmark, Germany, Italy and …

Year: 2013

Citations as recorded by: Google

44. Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs

Year: 2013

Citations as recorded by: Google

45. Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RA

Year: 2012

Citations as recorded by: Google

46. Meeting the challenge of the ageing of the population: issues in access to specialist care for arthritis

Year: 2012

Citations as recorded by: Google

47. Situation of rheumatology in Poland in 2012

Year: 2012

Citations as recorded by: Google

48. Анемия у больных ревматоидным артритом

Year: 2012

Citations as recorded by: Google

49. Management of rheumatoid arthritis: consensus recommendations from the Turkish League Against Rheumatism

Year: 2011

Citations as recorded by: Google

50. Challenges and changes in the Polish healthcare system

Year: 2011

Citations as recorded by: Google

51. NEFARMAKOLOŠKO LIJEČENJE BOLESNIKA SA SPONDILOARTROPATIJAMA NONPHARMACOLOGICAL TREATMENT OF PATIENTS WITH …

Year: 2011

Citations as recorded by: Google

52. [CITATION] [C] Romatoid Artritin Tedavisi: Türkiye Romatizma Araştırma ve Savaş Derneği Uzlaşı Önerileri

Year: 2011

Citations as recorded by: Google

53. Nefarmakološko liječenje bolesnika sa spondiloartropatijama

Year: 2011

Citations as recorded by: Google